Home>>Signaling Pathways>> Others>>SRI-37330

SRI-37330

目录号 : GC68451

SRI-37330是硫氧还蛋白相互作用蛋白(TXNIP)的小分子抑制剂。

SRI-37330 Chemical Structure

Cas No.:2322245-42-9

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥981.00
现货
1mg
¥490.00
现货
5mg
¥700.00
现货
10mg
¥1,120.00
现货
25mg
¥2,240.00
现货
50mg
¥3,360.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

SRI-37330 is a small molecule inhibitor of thioredoxin interacting protein (TXNIP) [1]. SRI-37330 helps protect β cells and increase their number by reducing TXNIP levels, thereby improving insulin secretion capacity [2-3]. SRI-37330 is mainly used to treat diabetes [4].

In adult murine ventricular cardiomyocytes (AMVCs), SRI-37330 (0-5μM; 24h) dose-dependently inhibited the expression of cleaved-Casp1 and TXNIP/NLRP3 in Doxorubicin-treated AMVCs [5]. In FTOoe A549 cells, SRI-37330 (10μM; 24h) significantly reduced the expression of TXNIP protein in cells and abolished the increase in the expression of pyroptosis-related proteins [6]. In rat INS-1 cells, SRI-37330 can significantly inhibit the expression of TXNIP [7].

In diabetic mice model, basal glucose production in the liver of mice treated with SRI-37330 (100mg/kg; po; 3 weeks) was significantly downregulated [7]. In high fat diet mice model, oral SRI-37330 (100mg/kg; po; 4 weeks) treatment protects against high-fat diet-induced glucose intolerance [8].

References:
[1]. Choi EH, Park SJ. TXNIP: A key protein in the cellular stress response pathway and a potential therapeutic target. Experimental & molecular medicine. 2023 Jul; 55(7): 1348-1356.
[2]. Datta S, Rahman MA, Koka S, et al. Mitigation of nicotine-induced podocyte injury through inhibition of thioredoxin interacting protein. Biomedicine & Pharmacotherapy. 2025 Jun 1; 187: 118110.
[3]. Dalle S, Abderrahmani A, Renard E. Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes. Frontiers in endocrinology. 2023 Mar 15; 14: 1076343.
[4]. Demir S, Nawroth PP, Herzig S, et al. Emerging targets in type 2 diabetes and diabetic complications. Advanced Science. 2021 Sep; 8(18): 2100275.
[5]. Ma Y, Wang Y, Chen R, et al. Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk. Signal Transduction and Targeted Therapy. 2025 May 14;10(1):1-26.
[6]. Xie WM, Su W, Liu XY, et al. FTO deficiency alleviates LPS-induced acute lung injury by TXNIP/NLRP3-mediated alveolar epithelial cell pyroptosis. American Journal of Respiratory Cell and Molecular Biology. 2024 May; 70(5): 351-363.
[7]. Thielen LA, Chen J, Jing G, et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metabolism. 2020 Sep 1; 32(3): 353-365.
[8]. Jo S, Jing G, Chen J, et al. Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism. 2025 Apr; 27(4): 2223-2231.

SRI-37330是硫氧还蛋白相互作用蛋白(TXNIP)的小分子抑制剂 [1]。SRI-37330通过降低TXNIP水平来保护β细胞并增加其数量,从而提高胰岛素分泌能力 [2-3]。SRI-37330主要用于治疗糖尿病 [4]

在成年小鼠心室肌细胞(AMVC)中,SRI-37330(0-5μM;24h)剂量依赖性地抑制了经Doxorubicin处理的AMVC中cleaved-Casp1和TXNIP/NLRP3的表达 [5]。在 FTOoe A549细胞中,SRI-37330(10μM;24h)显著降低了细胞中TXNIP蛋白的表达,并消除了细胞焦亡相关蛋白表达的增加 [6]。在大鼠INS-1细胞中,SRI-37330可显著抑制TXNIP的表达 [7]

在糖尿病小鼠模型中,经SRI-37330(100mg/kg;po;3周)治疗的小鼠肝脏基础葡萄糖生成显著下调 [7]。在高脂饮食小鼠模型中,口服SRI-37330(100mg/kg;po;4周)治疗可预防高脂饮食引起的葡萄糖不耐受 [8]

实验参考方法

Cell experiment [1]:

Cell lines

Adult murine ventricular cardiomyocytes (AMVCs)

Preparation Method

AMVCs were isolated and cocultured with 4T1 breast cancer cells in a Transwell system. The cells were treated with Doxorubicin (1μM) for 24h, followed by treatment with varying concentrations of VX765 (0–100nM), MCC950 (0–50nM), or SRI-37330 (0–5μM).

Reaction Conditions

0-5μM; 24h

Applications

SRI-37330 dose-dependently inhibited the expression of cleaved-Casp1 and TXNIP/NLRP3 in Doxorubicin-treated AMVCs.
Animal experiment [2]:

Animal models

High fat diet (HFD) mice model

Preparation Method

Mice on HFD mice were randomly assigned to experimental groups to be treated with oral SRI-37330 (100mg/kg in the drinking water) (n = 12) or (n = 3) or without SRI-37330 (n = 20) or (n = 4). Other treatments were as previously reported, metformin (250mg/kg), or empagliflozin (10mg/kg) in the drinking water, and leptin (7.2mg/kg i.p.).

Dosage form

100mg/kg; po; 4 weeks

Applications

Oral SRI-37330 treatment protects against high-fat diet-induced glucose intolerance.

References:
[1]. Ma Y, Wang Y, Chen R, et al. Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk. Signal Transduction and Targeted Therapy. 2025 May 14;10(1):1-26.
[2]. Jo S, Jing G, Chen J, et al. Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity. Diabetes, Obesity and Metabolism. 2025 Apr; 27(4): 2223-2231.

化学性质

Cas No. 2322245-42-9 SDF Download SDF
分子式 C16H19F3N4O2S 分子量 388.41
溶解度 DMSO : 100 mg/mL (257.46 mM; Need ultrasonic) 储存条件 Store at -20°C, stored under nitrogen
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.5746 mL 12.873 mL 25.746 mL
5 mM 0.5149 mL 2.5746 mL 5.1492 mL
10 mM 0.2575 mL 1.2873 mL 2.5746 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: